Cleaved-PLG (V98) Antibody

What is Cleaved-PLG (V98) Antibody and what is its specificity?

Cleaved-PLG (V98) Antibody is a rabbit polyclonal antibody that specifically recognizes the cleaved form of Plasminogen HC A short form (V98). The antibody detects endogenous levels of activated Plasminogen HC A short form protein resulting from cleavage adjacent to V98 . It was developed using a synthesized peptide derived from the human Plasminogen at the amino acid range 79-128 . The specificity of this antibody is particularly important for researchers studying plasminogen activation pathways, as it allows differentiation between the inactive zymogen and the cleaved, activated form of the protein.

The antibody specifically binds to the epitope within the 79-128 amino acid region of human Plasminogen, which becomes exposed after proteolytic processing. Its reactivity has been verified across human, mouse, and rat samples, making it valuable for comparative studies across these species .

What experimental applications is Cleaved-PLG (V98) Antibody validated for?

The Cleaved-PLG (V98) Antibody has been validated primarily for Western Blot (WB) and Enzyme-Linked Immunosorbent Assay (ELISA) applications . The recommended dilution ranges for optimal results are:

When designing experiments, researchers should first validate the antibody in their specific experimental conditions, including testing different dilutions within the recommended range to determine optimal signal-to-noise ratio. Unlike some antibodies that work across multiple applications, the Cleaved-PLG (V98) Antibody has been specifically validated for WB and ELISA, suggesting these methods provide the most reliable detection of the cleaved plasminogen form.

What is the biochemical profile and storage recommendations for Cleaved-PLG (V98) Antibody?

Understanding the biochemical characteristics and proper storage conditions is essential for maintaining antibody functionality and experimental reproducibility:

For optimal stability, the antibody should be stored at -20°C for up to 1 year from the date of receipt, with repeated freeze-thaw cycles strictly avoided . This storage recommendation is based on stability testing of antibody activity over time under different storage conditions. Some researchers recommend aliquoting the antibody upon receipt to minimize freeze-thaw cycles, which can cause protein denaturation and loss of binding activity.

What is the biological function of Plasminogen (PLG) and its cleaved form?

Human Plasminogen (PLG) is a crucial protein in the fibrinolytic system, primarily responsible for the conversion of fibrin into soluble fibrin degradation products, thereby facilitating the dissolution of blood clots . PLG is synthesized in the liver and circulates in the bloodstream as an inactive zymogen. Upon activation by plasminogen activators such as tissue plasminogen activator (tPA) and urokinase plasminogen activator (uPA), PLG is converted into plasmin, which exhibits proteolytic activity essential for various physiological processes .

The cleaved form of PLG that is recognized by the V98 antibody represents an activated state of the protein. This activation involves proteolytic processing that exposes catalytic domains, allowing the molecule to perform its fibrinolytic functions. Beyond fibrinolysis, cleaved PLG/plasmin is involved in:

• Wound healing and tissue remodeling

• Cellular migration and invasion

• Inflammatory response modulation

• Pathogen interaction and immune response

The V98 cleavage site is particularly significant as it represents a key processing point that influences plasmin activity regulation in both normal physiology and pathological conditions .

How does PLG cleavage occur in physiological and pathological conditions?

Plasminogen cleavage occurs through several mechanisms in both physiological and pathological contexts:

Physiological PLG Cleavage:

• Endogenous activators (tPA, uPA) cleave plasminogen at specific sites, particularly between Arg-560 and Val-561, generating the active two-chain plasmin molecule

• This activation is tightly regulated by plasminogen activator inhibitors (PAIs) and α2-antiplasmin

• The activation process often requires cofactors such as fibrin, which localizes plasminogen activation to sites of clot formation

Pathological PLG Cleavage:

• Bacterial pathogens can express plasminogen activators (e.g., streptokinase, staphylokinase) or directly bind plasminogen to facilitate invasion

• The Y. pestis Pla protein specifically cleaves between Arg-580 and Val-581, generating plasmin which facilitates bacterial migration and infection

• Dysregulated plasmin generation is associated with various thrombotic and hemorrhagic disorders

The Cleaved-PLG (V98) Antibody specifically recognizes the cleavage adjacent to V98, which represents one form of activated plasminogen. This specificity makes it valuable for distinguishing between different activation states in research contexts .

What methodological approaches are recommended for optimizing Cleaved-PLG (V98) Antibody in Western Blot experiments?

When optimizing Western Blot protocols for Cleaved-PLG (V98) Antibody, researchers should consider the following methodological refinements:

Sample Preparation Considerations:

• Incorporate protease inhibitors in lysis buffers to prevent ex vivo plasminogen activation

• Include phosphatase inhibitors when studying phosphorylation-dependent activation mechanisms

• Process samples rapidly at 4°C to minimize artifactual cleavage

• Consider using urea-based lysis buffers (6-8M) for difficult-to-extract membrane-associated forms

Optimization Protocol:

• Initial titration: Test antibody at 1:500, 1:1000, and 1:2000 dilutions against positive control samples (e.g., human U-87MG or A375 whole cell lysates)

• Blocking optimization: Compare BSA-based (3-5%) versus milk-based (5%) blocking buffers, as milk contains plasminogen which may interfere with specific detection

• Incubation conditions: Compare overnight incubation at 4°C versus 2-hour incubation at room temperature

• Signal development: For low abundance targets, consider enhanced chemiluminescence substrate with extended exposure times or fluorescent secondary antibodies for quantitative analysis

Controls to Include:

• Positive control: Samples with known cleaved PLG (e.g., plasmin-treated plasma)

• Negative control: PLG-depleted samples or CRISPR knockout cell lines

• Specificity control: Pre-incubation of antibody with immunizing peptide (amino acids 79-128) to confirm signal specificity

• Loading control: Probe for housekeeping proteins (β-actin, GAPDH) to normalize loading

This methodological approach, with systematic optimization of each parameter, significantly improves detection sensitivity and specificity when working with Cleaved-PLG (V98) Antibody in Western Blot applications.

How can researchers effectively use Cleaved-PLG (V98) Antibody to study cleavage-dependent PLG functions in thrombotic disorders?

Studying cleavage-dependent PLG functions in thrombotic disorders requires careful experimental design that leverages the specificity of the Cleaved-PLG (V98) Antibody:

Research Model Selection:

• Patient-derived samples: Collect plasma/serum from patients with known thrombotic disorders (e.g., portal vein thrombosis, deep vein thrombosis) alongside matched controls

• Animal models: Consider thrombosis models in mice/rats that recapitulate human disease mechanisms

• In vitro systems: Develop flow chamber models with controlled shear stress to mimic vascular conditions

Experimental Approaches:

• Comparative profiling: Quantify cleaved PLG (V98) levels across patient cohorts stratified by disease severity using ELISA

• Temporal studies: Monitor cleaved PLG (V98) levels during disease progression and in response to therapeutic interventions

• Functional correlation: Combine cleaved PLG (V98) detection with functional assays such as:

  • Clot lysis time (CLT) assays to measure fibrinolytic capacity

  • Permeability assays to assess fibrin clot structure and quality

  • Clot retraction assays to evaluate platelet-fibrin interactions

Data Analysis Framework:

• Establish normal baseline ranges for cleaved PLG (V98) in healthy controls

• Perform multivariate analysis to identify correlations between cleaved PLG levels and other hemostatic parameters

• Use competing risk survival analysis to evaluate the predictive value of cleaved PLG levels for thrombotic events

This integrated approach has successfully demonstrated that altered levels of cleaved plasminogen forms correlate with thrombotic risk in cirrhotic patients with portal vein thrombosis. Similar methodology could be applied to other thrombotic conditions, potentially revealing novel disease mechanisms and therapeutic targets.

How do post-translational modifications of PLG impact antibody recognition and what controls should be implemented?

Post-translational modifications (PTMs) of plasminogen can significantly impact Cleaved-PLG (V98) Antibody recognition, potentially leading to false negative or false positive results if not properly controlled:

Key PLG Post-Translational Modifications:

• Glycosylation:

  • N-linked glycans containing N-acetyllactosamine and sialic acid

  • O-linked glycans consisting of Gal-GalNAc disaccharide modified with up to 2 sialic acid residues (microheterogeneity)

  • These modifications can mask epitopes or create steric hindrance affecting antibody binding

• Phosphorylation:

  • Phosphorylation states may alter protein conformation and epitope accessibility

  • Phosphorylation can influence proteolytic susceptibility at cleavage sites

• Proteolytic Processing:

  • Different proteases generate distinct cleavage fragments

  • The V98 cleavage site may be affected by upstream or downstream processing events

Methodological Controls for PTM Impact Assessment:

Interpretation Guidelines:

• Changes in antibody signal after PTM-removing treatments suggest epitope masking

• Consistent detection across multiple antibodies targeting different epitopes increases confidence in results

• Correlation between functional assays and antibody detection strengthens biological relevance of findings

By implementing these controls, researchers can distinguish genuine biological variation in cleaved PLG from technical artifacts related to post-translational modifications, significantly enhancing data reliability and interpretability.

What are the technical considerations for developing multiplex assays incorporating Cleaved-PLG (V98) Antibody?

Developing robust multiplex assays that incorporate Cleaved-PLG (V98) Antibody requires careful consideration of several technical factors to ensure assay specificity, sensitivity, and reproducibility:

Antibody Compatibility Assessment:

• Cross-reactivity testing: Screen for potential cross-reactivity between the Cleaved-PLG (V98) Antibody and other antibodies in the multiplex panel

• Species compatibility: When using antibodies from multiple species, select appropriate secondary antibodies with minimal cross-reactivity

• Isotype consideration: As Cleaved-PLG (V98) is a rabbit IgG, pair it with antibodies of different isotypes or species when possible

Optimization Framework for Multiplex ELISA Systems:

• Sequential Dilution Matrix:

  Parameter	Optimization Range	Best Practice
  Primary antibody (Cleaved-PLG V98)	1:5000 - 1:20000	Begin with 1:10000 as recommended
  Detection antibody	1:1000 - 1:10000	Titrate with consistent antigen level
  Antigen concentration	0.1-10 ng/mL	Establish standard curve for quantification
  Blocking buffer	BSA vs. casein vs. commercial	Test each with background controls

• Signal Development Considerations:

  • Substrate selection based on desired sensitivity and instrument compatibility

  • Temporal coordination of signal development for multiple analytes

  • Signal isolation strategies (spectral separation for fluorescent systems)

• Validation Protocol for Multiplex Systems:

  • Spike-recovery experiments with known concentrations of target proteins

  • Cross-interference assessment between analytes

  • Comparison of singleplex vs. multiplex detection efficiency

  • Reproducibility assessment across multiple experiments and operators

Practical Implementation Example:
A successful multiplex assay could combine Cleaved-PLG (V98) Antibody with antibodies against related hemostatic markers (e.g., D-dimer, PAI-1, tPA) to create a comprehensive fibrinolytic profile. Such an approach has been successfully applied in studying portal vein thrombosis, where multiple hemostatic parameters were evaluated simultaneously .

How can researchers effectively use Cleaved-PLG (V98) Antibody to investigate pathogen-PLG interactions?

Plasminogen interactions with pathogen proteins represent a significant virulence mechanism, as many pathogens exploit plasminogen to evade host defenses . The Cleaved-PLG (V98) Antibody offers valuable methodological approaches to investigate these interactions:

Experimental Models for Studying Pathogen-PLG Interactions:

• In vitro binding assays:

  • Solid-phase binding assays with immobilized bacterial proteins and purified PLG

  • Flow cytometry with intact bacteria and fluorescently-labeled plasminogen

  • Surface plasmon resonance for real-time interaction kinetics

  • Pull-down assays using the Cleaved-PLG (V98) Antibody to identify novel bacterial interactors

• Activation analysis systems:

  • Chromogenic substrate assays to measure bacterial-induced plasminogen activation

  • Zymography to detect plasmin activity after bacterial exposure

  • Immunoblotting with Cleaved-PLG (V98) Antibody to specifically detect V98 cleavage after bacterial interaction

• Functional consequence assessment:

  • Extracellular matrix degradation assays

  • Bacterial invasion models in cell culture

  • Fibrin overlay assays to measure proteolytic activity

Methodological Case Study: Yersinia pestis PLG Interaction
The search results indicate that Y. pestis Pla protein specifically cleaves PLG between Arg-580 and Val-581, generating plasmin which facilitates bacterial migration and infection . A comprehensive investigation could employ:

• Comparative cleavage analysis:

  • Side-by-side analysis of host protease vs. Pla-mediated PLG cleavage using Cleaved-PLG (V98) Antibody

  • Time-course experiments to determine cleavage kinetics

  • Mutational analysis of bacterial Pla to identify critical residues for interaction

• Inhibition strategies:

  • Screening for inhibitors that specifically block pathogen-mediated PLG activation

  • Using Cleaved-PLG (V98) Antibody to confirm inhibition of specific cleavage events

  • Evaluating effects of inhibition on bacterial virulence

This methodological approach has significant translational potential, as understanding the molecular details of pathogen-PLG interactions could lead to novel anti-infective strategies targeting these specific interactions.

What approaches should researchers employ to verify the specificity of results when using Cleaved-PLG (V98) Antibody?

Verifying antibody specificity is critical for ensuring experimental validity. For Cleaved-PLG (V98) Antibody, a multi-faceted verification approach is recommended:

Comprehensive Specificity Verification Protocol:

• Positive and Negative Control Samples:

  • Positive controls: Plasmin-treated samples with known V98 cleavage

  • Negative controls: Samples from PLG-knockout models or PLG-depleted samples

  • Competing peptide controls: Pre-incubation of antibody with immunizing peptide (aa 79-128)

• Cross-Reactivity Assessment:

  • Test against other proteolytically processed plasma proteins (e.g., fibrinogen fragments)

  • Evaluate recognition patterns in multi-species samples (human, mouse, rat)

• Orthogonal Validation Methods:

  Validation Method	Implementation Approach	Expected Outcome
  Mass spectrometry	Immunoprecipitate target with antibody followed by MS analysis	Identification of specific cleavage site
  Genetic manipulation	CRISPR/Cas9 to modify the V98 cleavage site	Loss of antibody signal
  Alternative antibodies	Use antibodies targeting different PLG epitopes	Concordant detection patterns
  Functional correlation	Correlate antibody signal with functional PLG assays	Positive correlation with activity

• Technical Controls:

  • Include isotype control antibodies in parallel experiments

  • Perform antibody titration to establish signal specificity

  • Compare results across different detection methods (ELISA, WB, etc.)

Case Example From Research:
In studies examining von Willebrand factor-cleaving protease inhibitors, which show some methodological similarities, researchers performed mixing studies with various dilutions of plasma samples. This approach helped establish specificity by demonstrating dose-dependent inhibition effects . Similar mixing studies could be applied to verify Cleaved-PLG (V98) Antibody specificity, particularly in complex biological samples.

How can Cleaved-PLG (V98) Antibody be utilized to study fibrinolytic dysregulation in liver disease?

Liver disease presents a complex hemostatic environment where both pro-thrombotic and pro-hemorrhagic alterations can occur. The Cleaved-PLG (V98) Antibody offers unique research opportunities in this context:

Research Design Framework for Liver Disease Studies:

• Patient Cohort Stratification:

  • Categorize by etiology (viral, alcoholic, MAFLD) and disease severity (Child-Pugh or MELD score)

  • Include both compensated and decompensated cirrhotic patients

  • Record presence of complications (portal vein thrombosis, variceal bleeding)

• Comprehensive PLG Activation Assessment:

  • Quantify Cleaved-PLG (V98) levels using standardized ELISA protocols

  • Correlate with conventional fibrinolytic markers (D-dimer, PAI-1)

  • Measure functional plasmin generation capacity in patient samples

• Integrated Hemostatic Profiling:

  • Combine Cleaved-PLG detection with assessment of:

    • Clot lysis time (CLT) to measure fibrinolytic capacity

    • Fibrin clot permeability (Ks) to assess clot structure

    • Clot retraction to evaluate platelet-fibrin interactions

Methodological Approach Based on Portal Vein Thrombosis Research:
Research on portal vein thrombosis in cirrhotic patients offers a valuable methodological template. In these studies, researchers combined:

• Clinical Assessment:

  • Regular Doppler-US evaluation every 6 months

  • Comprehensive clinical and laboratory data collection

• Specialized Hemostatic Testing:

  • Measuring microparticles using phosphatidylserine capture and functional assays

  • Quantifying NETs (neutrophil extracellular traps) through MPO-DNA complexes

  • Evaluating clot properties through permeability and retraction assays

• Statistical Analysis Strategies:

  • Competing risk survival analysis to evaluate PVT development predictors

  • Time-dependent covariate analysis for longitudinal assessment

By adapting this methodological framework and incorporating Cleaved-PLG (V98) Antibody detection, researchers can gain new insights into the role of plasminogen activation in liver disease progression and complications, potentially identifying novel therapeutic targets.